文献速递白血病

儿童方案治疗青少年及年轻成人急性淋巴细胞白血病:CALGB 10403研究结果

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
PubMed 文献 · Blood · 2019-01-18

CALGB 10403是一项前瞻性研究,采用与儿童肿瘤协作组AALL0232研究相同剂量和方案的儿童方案,治疗成人治疗团队管理的初诊急性淋巴细胞白血病青少年及年轻成人患者,2007至2012年共入组318例、295例可评估,中位年龄24岁,治疗相关死亡率3%,3年无事件生存率59%、3年总生存率73%,中位无事件生存期78.1个月,优于历史对照的30个月。

要点

  • 儿童方案用于40岁及以下急性淋巴细胞白血病青少年及年轻成人可行且有效,生存率优于历史对照。
  • 总体治疗相关死亡率为3%,缓解后死亡仅2例。
  • CALGB 10403可被视为提高该人群生存的新治疗标准基础。

核心结论

  • 儿童方案用于40岁及以下急性淋巴细胞白血病青少年及年轻成人可行且有效,生存率较历史对照改善。
  • CALGB 10403可被视为在此基础上进一步提高该人群生存的新治疗标准。

研究设计与样本

  • 前瞻性研究CALGB 10403,剂量和方案与儿童肿瘤协作组AALL0232研究相同。
  • 2007至2012年共入组318例,295例符合条件并可评估疗效,中位年龄24岁(范围17-39岁)。

主要发现

  • 总体治疗相关死亡率为3%,缓解后死亡仅2例。
  • 中位无事件生存期为78.1个月(95%CI 41.8至未达到),超过历史对照30个月(95%CI 22-38个月)的两倍。
  • 3年无事件生存率为59%(95%CI 54%-65%)。
  • 中位总生存期未达到,估计3年总生存率为73%(95%CI 68%-78%)。
  • 与更差治疗结局相关的治疗前危险因素包括肥胖和Philadelphia样基因表达特征。

临床怎么用

  • 作者认为CALGB 10403可被视为提高青少年及年轻成人急性淋巴细胞白血病生存的新治疗标准基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019. PMID: 30658992. doi:10.1182/blood-2018-10-881961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。